11月21日，第五届华夏大健康产业发展暨康复服务大会在京举行。会上公布了系列创新典型案例，以岭 药业凭借其中药创新领域的卓越成就，入选"2025年度中医药创新典型案例"。 以岭药业始终将研发作为企业发展的核心驱动力，2025年前三季度，公司研发投入达5.44亿元，占营业 收入比重9.27%，持续领跑行业。2019至2024年间，累计研发投入已突破50亿元，形成"投入－转化－ 再投入"的良性循环，为持续产出符合中国人生命基因与体质特点的"中国药"奠定坚实基础。 在中药创新成果方面，2025年以岭药业研发管线成果丰硕。中药1.1类新药芪防鼻通片获国家药监局批 准上市，后又在澳门上市，成为澳门首个注册上市的中成药创新药。此外，芪桂络痹通片、小儿连花清 感颗粒等4款中药新药已进入申报阶段，另有5款中药处于临床研究，覆盖呼吸、风湿免疫、神经系统等 重大疾病领域，持续拓展中药治疗边界。截至目前，以岭药业共拥有17个专利中药，覆盖心脑血管、呼 吸系统、内分泌等重大疾病领域，其中11个品种纳入国家医保目录，5个进入国家基药目录，切实减轻 患者用药负担。 以岭药业不仅注重新药研发，更以高标准的循证医学研究推动中医药走向世界。其 ...

Core Insights - The forum focused on the high-quality development of the silver economy, emphasizing the role of technology in enhancing the quality of life for the elderly [7] - TCM company Tianyao Darentang shared its innovative approaches and achievements in the silver health sector, positioning itself as a "health guardian" for the elderly [1][6] Company Overview - Tianyao Darentang has a 500-year heritage in traditional Chinese medicine (TCM) and operates under the principle of "guarding tradition while innovating" [3] - The company holds four time-honored brands and five national intangible cultural heritage techniques, showcasing its commitment to preserving TCM wisdom [3] Innovation and Technology - The company has invested 370 million yuan to establish a top-tier production base for pill manufacturing, utilizing AI for raw material testing and automated production processes [4] - Advanced technologies such as 3D fluorescence imaging and single-cell sequencing are employed to analyze the mechanisms of TCM, ensuring both efficacy and evidence-based support [4] Market Context - With over 310 million people aged 60 and above in China and a silver economy valued at over 7 trillion yuan, there is a significant market opportunity for health solutions targeting this demographic [4] - Tianyao Darentang aims to address health challenges faced by the elderly, including emergency care gaps and chronic diseases, through its product offerings [4] Collaborative Initiatives - The company proposed several collaborative initiatives, including integrating "emergency corners" and "health service stations" into community infrastructure to leverage policy benefits [4] - It expressed willingness to share smart manufacturing technologies and build a big data platform for silver health, as well as to establish a nationwide emergency care network [4] Future Vision - Tianyao Darentang is committed to empowering traditional TCM with technology, aiming to be a reliable health guardian for the elderly and contribute to the high-quality development of the silver economy [6]

| 2025排名 | 排名变化 | 姓名 | 财富 | 涨幅 | 公司 | 居住地 | 主业 | 年齡 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (亿元人民币) | | | | | | | 126 | -19 | 刘伟 | 442 | 11% | 米哈游 | 上海 | 游戏 | 38 | | 126 | -38 | 谢青 | 445 | 196 | 长度 | 美国旧等山 | 网络安全 | 62 | | 126 | -38 | 蔡明忠家族 | 445 | 1% | 昌邦 | 台湾台北 | 壬戌服务 | ୧୦ | | 126 | -36 | 米高·嘉道理家族 | 445 | 2% | 中田 | 香港 | 能源 | 84 | | 130 | New | 区一佳 | 440 | New | 脑再生 | 播港 | 生物制药 | 53 | | 130 | 241 | 袁富根家族 | 440 | 226% | 东山精密 | 江办办" | 精密铸件 | 15 | | 130 | -33 | 未建波家族 | 440 | ୧୫୧ | 南山 ...

Core Viewpoint - Yiling Pharmaceutical demonstrates strong operational resilience and growth potential in its Q3 2025 report, showcasing impressive performance in revenue, profit quality, and cash flow improvement, laying a solid foundation for stable annual growth [1][2]. Financial Performance - For the first nine months of 2025, Yiling Pharmaceutical achieved revenue of 5.868 billion yuan, with net profit increasing by 80.33% year-on-year to 1 billion yuan, and non-deductible net profit rising by 90.5% to 966 million yuan [1]. - The net cash flow from operating activities reached 1.278 billion yuan, a staggering increase of 296.19% year-on-year, indicating high operational quality [1]. - Basic earnings per share were 0.5988 yuan, reflecting an 80.31% increase compared to the same period in 2024 [1]. Market Reaction - Following the positive news, Yiling Pharmaceutical's stock opened at 17.35 yuan per share and peaked at 18.23 yuan, closing at 17.72 yuan, up 3.32% [1]. Industry Positioning - In a challenging pharmaceutical industry environment, Yiling Pharmaceutical stands out as a leading innovator in traditional Chinese medicine, optimizing product structure and enhancing cash flow management [2]. - The company focuses on the research, production, and sales of patented innovative traditional Chinese medicine while actively expanding into biopharmaceuticals and health industries, creating a synergistic development model [2]. Research and Development - Yiling Pharmaceutical has invested a total of approximately 4 billion yuan in R&D from 2019 to 2023, with over 900 million yuan allocated in 2024, representing 13.94% of its revenue, maintaining a leading position in R&D intensity within the industry [2][3]. - In the first three quarters of 2025, the company invested 544 million yuan in R&D, accelerating the transformation of innovative traditional Chinese medicine [3]. Product Development - Yiling Pharmaceutical has made significant progress with several products since 2025, including the approval of traditional Chinese medicine "Qifang Bitong Pian" and the chemical raw material "Letrozole," with multiple product applications under review [3]. - The biopharmaceutical segment is also accelerating, with four products in clinical and application stages, including the NDA application for "Phenylbutazone Injection" [3]. Future Outlook - Yiling Pharmaceutical's patented traditional Chinese medicine products, guided by the theory of "Luo Disease," have demonstrated clear clinical efficacy and significant market potential [4]. - The company aims to enhance its core technologies and products while focusing on key areas such as respiratory, endocrine, and digestive health, with plans for international expansion and innovation [4].

Core Insights - Dong'e Ejiao reported a revenue of 4.766 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 10.1%, with a net profit of 1.274 billion yuan, up 10.58% [1] - The company's gross profit margin increased by 3.33 percentage points to 73.69% during the reporting period, attributed to stable growth in core product lines and a focus on high-margin categories [1] Product Performance - The core product matrix, including Ejiao blocks and compound Ejiao syrup, continued to support the company's growth, with both product lines showing steady growth and increased market share [2] - Ejiao blocks maintained a leading position in the OTC market, with ongoing strategies to attract diverse consumer groups through high-end and youth-oriented marketing [2] - The introduction of low-sugar certified products under the "Peach Blossom Princess Ejiao Cake" brand has effectively increased repurchase rates among female consumers [2] Market Expansion Strategies - The company is actively targeting the silver economy and men's health sectors, with Ejiao blocks being recognized for their blood-nourishing properties among the elderly [2] - The "Royal Weichang 1619" brand focuses on men's health, addressing issues like kidney deficiency and fatigue, with products designed to penetrate the male vitality supplement market [3] Strategic Collaborations and Investments - Dong'e Ejiao has partnered with China Resources to establish a 1 billion yuan pharmaceutical investment fund, focusing on traditional Chinese medicine and synthetic biology [3] - The company has opened a flagship health store in Hong Kong, enhancing its global presence and facilitating entry into Southeast Asian and Belt and Road markets [4] Support from Parent Company - The integration of resources from the China Resources Group has significantly improved Dong'e Ejiao's production efficiency and product quality, establishing a competitive advantage in the market [5]

Core Insights - Zhongheng Group has achieved significant milestones in the field of traditional Chinese medicine innovation, including the establishment of the "ASEAN Traditional Chinese Medicine Research Center" in collaboration with Shanghai University of Traditional Chinese Medicine, which has been recognized as a key innovation hub in Guangxi [1][2] - The company’s subsidiary, Wuzhou Pharmaceutical, has been recognized as one of the "Top 100 High-tech Enterprises in Guangxi" for two consecutive years, highlighting its innovation capabilities and industry competitiveness [1][2] Research and Development - The ASEAN Traditional Chinese Medicine Research Center focuses on key areas such as cardiovascular diseases and tumors, with a comprehensive development path that includes new drug development and secondary development of exclusive varieties [1] - Currently, 15 projects have been initiated, including three new traditional Chinese medicine drugs for treating specific conditions and one chemical drug for atopic dermatitis [1] - The center has also launched five secondary development projects for exclusive varieties, including injectable thrombolytic agents and various health products [1] Academic and Collaborative Efforts - The center has secured funding exceeding 2 million yuan through various projects, including one national key research and development project and two Guangxi natural science fund projects [2] - Collaboration with key laboratories and universities is being strengthened, with 11 experts from Shanghai University of Traditional Chinese Medicine invited to participate in projects [2] - Wuzhou Pharmaceutical has initiated over 40 research projects, including 4 national-level and 11 regional-level projects, with 25 projects successfully completed [2]

Core Viewpoint - The article highlights the innovative strategies and cultural heritage techniques employed by Guilin Sanjin during the 14th Five-Year Plan period, emphasizing the company's commitment to quality and market expansion in the traditional Chinese medicine sector [2][13]. Group 1: Heritage Techniques Empowering Products - Guilin Sanjin's flagship product, Sanjin Watermelon Frost, has a history of over 200 years, with its modern production techniques improving upon traditional methods to achieve industrial-scale production [4][5]. - The company has successfully integrated modern Chinese medicine theories with traditional craftsmanship, resulting in high-purity products with reduced production cycles and no pollution [5]. - The "Guilin Sanjin Watermelon Frost Production Technique" was included in the Guilin Intangible Cultural Heritage List in 2024, showcasing the company's dedication to preserving and innovating traditional practices [5]. Group 2: Market Strategy and Consumer Focus - The company adopts a "thin profit margin, high sales volume" strategy, ensuring affordable pricing for consumers, with retail prices for Sanjin Watermelon Frost products ranging from a few to several tens of yuan [7]. - Over 90% of pharmacies in China carry Sanjin Watermelon Frost products, reflecting the company's strong market presence and consumer trust built over decades [7]. - The company maintains a comprehensive cost control system across its production processes, allowing it to offer high-quality products at competitive prices [7]. Group 3: Innovation-Driven Development - During the 14th Five-Year Plan, Guilin Sanjin has focused on innovation, establishing a joint innovation platform for traditional Chinese medicine and actively participating in national and regional research projects [9][10]. - The company has made significant advancements in its product lines, with multiple iterations of existing products to enhance efficacy and adapt to market needs [10][11]. - In the biopharmaceutical sector, Guilin Sanjin's subsidiary, Baoshan Biotech, is developing innovative drugs for autoimmune diseases and has received clinical approvals for several products [10][11]. Group 4: Supply Chain and Distribution - Guilin Sanjin employs a competitive bidding process for sourcing raw materials, ensuring quality and cost-effectiveness in its supply chain [12]. - The company has established a robust distribution network with nearly 100 main distributors and over a thousand sub-distributors, facilitating widespread market access [12]. - Currently, 18 of the company's products are registered and sold in 17 countries and regions, enhancing its international presence [13].

Core Viewpoint - Guilin Sanjin is leveraging traditional craftsmanship and innovative strategies to enhance product quality and drive growth during the 14th Five-Year Plan period [3][10]. Group 1: Product Innovation and Heritage - The company's flagship product, Sanjin Watermelon Frost, has a history of over 200 years and has been modernized through innovative production techniques that ensure high purity and effectiveness while reducing production time and environmental impact [3][4]. - Guilin Sanjin's commitment to traditional techniques has led to the successful inclusion of "Guilin Sanjin Watermelon Frost Production Technique" in the Guilin Intangible Cultural Heritage list in 2024, affirming the company's role in preserving and revitalizing traditional Chinese medicine [3][10]. Group 2: Market Strategy and Consumer Focus - The company adopts a "thin profit margin, high sales volume" strategy, ensuring affordable pricing for its products, which are widely available in over 90% of pharmacies across China [6][10]. - Sanjin Watermelon Frost and Sanjin Tablets have been market leaders for over 30 years, achieving a stable market share due to their consistent efficacy and consumer trust [6][10]. Group 3: Research and Development - During the 14th Five-Year Plan, Guilin Sanjin has received multiple awards for its research projects, highlighting its strong capabilities in scientific innovation [5][10]. - The company is actively involved in the development of innovative drugs and has made significant improvements to existing products, with Sanjin Watermelon Frost undergoing eight rounds of innovation [8][9]. Group 4: Supply Chain and Distribution - Guilin Sanjin maintains a robust supply chain with long-term relationships with suppliers, ensuring a steady supply of key raw materials for its products [10]. - The company has established a mature distribution network with nearly 100 main distributors and over 2,000 chain pharmacies, facilitating its market reach [10]. Group 5: International Expansion - Guilin Sanjin has successfully registered and launched 18 products in 17 countries and regions, expanding its presence in markets along the Belt and Road Initiative [10].

Core Insights - The 2025 China International Service Trade Fair, themed "Digital Intelligence Leading the Way, Service Trade Renewed," focuses on health and wellness services, showcasing innovations in the medical and healthcare sectors [1][2] Group 1: Health and Wellness Innovations - The health service exhibition features advancements in artificial intelligence, digital healthcare applications, and medical service solutions, allowing attendees to experience the impact of technology on health management [3] - Notable innovations include a home medical-grade ECG monitoring device developed by a team from Fuwai Hospital and a groundbreaking electromagnetic-driven intramedullary nail created in collaboration with Tsinghua University [3][4] - The "Liver and Gallbladder Super Doctor Intelligent System" from Tsinghua Chang Gung Hospital provides specialized knowledge support for liver disease diagnosis and treatment, enhancing the capabilities of primary care physicians [4] Group 2: Integration of Traditional Chinese Medicine (TCM) and Technology - TCM institutions showcased the integration of traditional practices with modern technology, such as the "Guangyi·Qizhi Model 2.0" that enhances TCM diagnostic processes through AI [5] - Beijing Tongrentang presented a variety of health service experiences, including a smart medication service that offers tailored health solutions for different demographics [6][7] - The introduction of herbal toothpaste "Yin Yang Su" reflects TCM's adaptation to modern health needs, emphasizing natural ingredients for oral health [7] Group 3: Elderly Care Solutions - The aging population's needs are addressed through diverse and personalized elderly care solutions, such as the "Five-in-One" service system by Shoushan Fuhai, which integrates care, medical services, nutrition, housing, and support [8] - Xinyue Health introduced the "Home Elderly Care Kit" and "Ten Thousand Doctors" health service model, focusing on professional and precise home care solutions [8]

Group 1: Industry Development - The provincial government is focusing on developing county-level industries to enhance local economic growth, particularly in Sanmenxia City [3] - Le's Tongren Sanmenxia Pharmaceutical Co., Ltd. is highlighted as a high-tech enterprise integrating traditional Chinese medicine cultivation, research, production, and sales [3] - Emphasis is placed on leveraging local medicinal materials and promoting collaborative innovation in traditional Chinese medicine and modern science [3] Group 2: Environmental Protection - A recent provincial meeting addressed the need for enhanced ecological environment protection measures [4] - Liu Ning emphasized the importance of ecological restoration in mining areas as part of the political responsibility to implement Xi Jinping's ecological civilization thoughts [4] - The focus is on a systematic approach to pollution control, including source reduction, process control, and end treatment [4] Group 3: Cultural and Tourism Integration - The Daxian Pit Courtyard is recognized as a national intangible cultural heritage, with efforts to protect and develop it scientifically [6] - There is a call to integrate local customs and culture into tourism development, aiming to create a pillar industry from cultural tourism [6] - The government aims to promote rural revitalization through urban-rural integration and the development of a modern industrial system [6]